Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 04 Dec 2019
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 05 Dec 2019
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

Endocrine therapy negatively affects QoL in postmenopausal breast cancer patients

12 Nov 2019

Quality of life (QoL) in breast cancer patients worsens 2 years following diagnosis with different courses by treatment received, a study has found. Specifically, endocrine therapy (ET) exerts a major detrimental impact on QoL as opposed to chemotherapy (CT) having a transient negative effect in postmenopausal patients.

Researchers prospectively collected patient-reported outcomes (PROs) in 4,262 breast cancer patients, among whom 2,675 (62.8 percent) were postmenopausal, using the European Organization for Research and Treatment of Cancer QLQ-C30/BR23 questionnaires within the CANTO trial.

In the cohort, 81.9 percent of patients received ET and 52.8 percent received CT. The primary endpoint of QLQ-C30 summary score (C30-SumSc) deteriorated over 2 years after diagnosis, with ET having a persistent negative impact on the C30-SumSc (p-interaction=0.004) but not CT (p-interaction=0.924).

ET negatively affected the following C30-SumSc domains: role and social function, pain, insomnia, systemic therapy side-effects, and breast symptoms. This treatment was also associated with further reductions in emotional function and future perspective recovery.

On the other hand, while CT had no impact on the C30-SumSc at 2 years, treatment was linked to deteriorations in physical and cognitive function, dyspnoea, financial difficulties, body image, and breast symptoms.

The present data question the common idea that ET is an innocent player in the QoL arena, according to the researchers. It is important to consider the differential effect of treatment classes by menopausal status on QoL when discussing optimal adjuvant therapy options and survivorship care with breast cancer patients, as such an effect may have implications for adherence and long-term health and psychosocial outcomes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 04 Dec 2019
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 05 Dec 2019
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).